These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 16143524)
1. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524 [TBL] [Abstract][Full Text] [Related]
2. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418 [TBL] [Abstract][Full Text] [Related]
3. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II. Kiselyov AS; Semenov VV; Milligan D Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892 [TBL] [Abstract][Full Text] [Related]
4. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II. Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647 [TBL] [Abstract][Full Text] [Related]
6. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases. Kiselyov AS; Semenova M; Semenov VV; Piatnitski E Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640 [TBL] [Abstract][Full Text] [Related]
7. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531 [TBL] [Abstract][Full Text] [Related]
8. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. Kiselyov AS; Semenova M; Semenov VV Bioorg Med Chem Lett; 2009 Feb; 19(4):1195-8. PubMed ID: 19124243 [TBL] [Abstract][Full Text] [Related]
9. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257 [TBL] [Abstract][Full Text] [Related]
10. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. Kiselyov AS; Piatnitski E; Semenova M; Semenov VV Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072 [TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433 [TBL] [Abstract][Full Text] [Related]
13. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Hess-Stumpp H; Haberey M; Thierauch KH Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376 [TBL] [Abstract][Full Text] [Related]